Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.32 |
| ▸ | SCD | O00767 | 2/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | CPT1A | P50416 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.30 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24158660 | 0.89 | WNT1 (0.32) | RIPK1HPGDSCD5KCNQ3KCNQ2 | |
| SCHEMBL19876673 | 0.81 | USP2 (0.40) | RIPK1LMNA | |
| SCHEMBL28369337 | 0.81 | TP53 (0.40) | HPGDLMNA | |
| SCHEMBL28885941 | 0.81 | TP53 (0.40) | HPGDLMNA | |
| SCHEMBL21033955 | 0.77 | RIPK1 (0.38) | RIPK1SCD5SCDGPR35ALOX15 | |
| SCHEMBL21033347 | 0.75 | RIPK1 (0.38) | RIPK1HRH3 | |
| SCHEMBL21033243 | 0.73 | RIPK1 (0.44) | RIPK1SCD5SCDHRH3 | |
| SCHEMBL3308706 | 0.72 | RIPK1 (0.35) | RIPK1 | |
| SCHEMBL21570216 | 0.70 | PTGER4 (0.36) | HPGDPTGER4LMNA | |
| SCHEMBL2325818 | 0.68 | WDR5 (0.49) | HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220340535-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4029868-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3793565-A1 | MCL-1 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | RIPK1 830/4885HPGD 2028/4885PTGER4 4483/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | RIPK1 830/4885HPGD 2028/4885PTGER4 4483/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | RIPK1 830/4885HPGD 2028/4885PTGER4 4483/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | RIPK1 830/4885HPGD 2028/4885PTGER4 4483/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | RIPK1 830/4885HPGD 2028/4885PTGER4 4483/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | RIPK1 830/4885HPGD 2028/4885PTGER4 4483/4885 |
| US-20220340535-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | RIPK1 830/4885HPGD 2028/4885PTGER4 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.